The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.00
Bid: 295.00
Ask: 299.00
Change: -8.00 (-2.63%)
Spread: 4.00 (1.356%)
Open: 292.00
High: 298.00
Low: 292.00
Prev. Close: 304.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks down as aggressive US Fed rate hike looms

Tue, 03rd May 2022 12:14

(Alliance News) - Stock prices in London were lower at midday on Tuesday following the long bank holiday weekend in the UK, as markets globally prepare for a sharp US interest rate hike and similar moves by other central banks as they struggle to control inflation.

All eyes are on the conclusion on Wednesday of the Federal Reserve's two-day policy meeting, where it is expected to lift borrowing costs by half a percentage point. It would be the first time since 2000 that the US central bank has raised rates by 50 basis points at one meeting.

Earlier Tuesday, Australia joined the tightened cycle started by central banks elsewhere. The Sydney-based central bank raised the main lending rate by 25 basis points to 0.35%, the first increase since November 2010.

The FTSE 100 index was down 32.64 points, or 0.4%, at 7,511.91. The mid-cap FTSE 250 index was down 12.02 points, or 0.1%, at 20,696.69. The AIM All-Share index was down 2.31 points, or 0.1%, at 1,019.95.

The Cboe UK 100 index was down 0.7% at 745.25. The Cboe 250 was down 0.5% at 18,172.69. The Cboe Small Companies climbed 0.1% to 15,174.74.

In mainland Europe, the CAC 40 in Paris was up 0.2% and the DAX 40 in Frankfurt was up 0.4%.

"Markets are particularly worried about lockdown in China and how fast US interest rates might go up. We'll get clarity on the latter tomorrow when the Federal Reserve gives its latest policy decision, with markets expecting half a percentage point increase in the Fed Funds rate. Central banks typically raise rates by a quarter percentage point, but the Fed is under pressure to be more aggressive to combat rising inflation," said AJ Bell's Russ Mould.

The Bank of England will announce its own rate decision on Thursday.

"Can the BoE surprise with a 50bps hike at some point this year? The short answer: it's a long shot," commented Sanjay Raja, senior economist at Deutsche Bank. "While a bigger move may be on the table in the coming meetings, we see...reasons why a 50bps move remains unlikely in the UK, despite other central banks upping the ante for bigger moves."

Raja noted that the UK central bank moved early, so it doesn't need to catch-up with global peers. As well, more so than other advanced economies, the UK is at risk of falling into recession.

In the FTSE 100, M&G was up 3.0% at midday on Tuesday, after HSBC raised the investment manager to 'buy' from 'hold'.

In addition, St James's Place was up 1.9% after HSBC also upgraded the wealth manager to 'buy' from 'hold'.

BP was up 2.0%. The oil major swung to a first-quarter loss due to its decision to exit from its shareholding in Rosneft in response to Moscow's invasion of Ukraine; however on an underlying basis, the oil major reported a big jump in profit.

For the three months that ended March 31, BP swung to an attributable loss of USD20.38 billion from a USD4.67 billion profit in the first quarter last year. BP said the reported result included pretax adjusted items of USD30.8 billion.

By its preferred metric, BP swung to a replacement cost loss of USD23.04 billion from a replacement cost profit of USD3.33 billion the year before.

The London-based firm attributed the loss to its decision to exit its near-20% shareholding in state-owned Russian oil firm Rosneft. BP said that, in the first quarter, the total post-tax charge for this was USD25.5 billion.

On an underlying replacement cost basis, BP reported a profit of USD6.25 billion, up 54% from USD4.07 billion in the fourth quarter of last year and more than doubled from USD2.63 billion a year ago.

BP raised its first-quarter dividend by 4.0% to 5.46 cents from 5.25 cents the year before. Further, during the first quarter BP generated surplus cash flow of USD4.1 billion and said it intends to execute a USD2.5 billion share buyback prior to announcing its second quarter results.

Rival oil producer Shell, which posts its own first-quarter numbers on Thursday, was down 1.0%.

BP's results come as calls from the opposition Labour Party for a windfall tax on UK oil majors grow louder, as the country grapples with a cost-of-living crisis.

Last week, UK Chancellor of the Exchequer Rishi Sunak appeared to distance himself from such a tax but did not entirely rule it out.

The chancellor called on companies making generating large profit to invest the cash back into the UK instead.

"It sounds appealing. 'Great, we're taxing bad energy companies more, that will solve all our problems'," he said in an interview with Mumsnet. "The reason we haven't gone down that road is, really simply…we need to invest more. That's why we haven't gone for some extra tax. Because what I don't want to do is discourage investment in our own energy supplies."

The view was echoed by UK Prime Minister Boris Johnson who said on Tuesday that a windfall tax on big energy firms would deter investment and make it harder to meet the country's net-zero environmental goals.

At the other end of the large-caps, Segro was the worst performer, down 7.4%. Kepler Cheuvreux downgraded the warehouse property investor to 'hold' from 'reduce'.

In the FTSE 250, Auction Technology Group was the best performer, up 7.0%, after JPMorgan raised the online auction operator to 'overweight' from 'neutral'.

Energean was up 4.5%. Subsidiary Energean Israel signed a gas sales agreement with the East Hagit Power Plant Ltd Partnership.

Under the agreement, Energean will supply gas to East Hagit for a term of 15 years, with a total contract quantity of up to 12 billion cubic feet. Energean said the agreement has the potential to generate revenue of up to USD2 billion over the offtake period.

On AIM, Hutchmed (China) was down 15%, after the drugmaker said the US Food & Drug Administration has rejected its surufatinib for treatment of pancreatic neuroendocrine tumours.

In a complete response letter, the FDA said the current data package, based on two positive phase three trials in China and one bridging study in the US, does not support an approval in the US "at this time".

The FDA said a multi-regional clinical trial of surufatinib required for US approval. Surufatinib was approved in China for the treatment of pNETs and extra-pancreatic neuroendocrine tumours in June 2021 and December 2020, respectively.

The dollar was higher across the board as the US Federal Reserve's two-day policy meeting gets underway. The pound was quoted at USD1.2512 at midday on Tuesday, down from USD1.2568 at the London equities close Friday.

The euro was priced at USD1.0517, down from USD1.0547. Against the Japanese yen, the dollar was trading at JPY130.11, up from JPY129.68.

On the economic front, UK manufacturing sector activity edged higher last month on increased intakes of new business against a backdrop of rising price inflationary pressures, S&P Global said.

The UK S&P Global-CIPS manufacturing purchasing managers' index was 55.8 points in April, up slightly from the preliminary estimate of 55.3 and the score of 55.2 registered in March.

S&P said the start of the second quarter saw a mild growth acceleration in the UK manufacturing sector. The rate of expansion in output improved from March's five-month low, leading to a further solid increase in staffing levels.

Brent oil was quoted at USD106.51 a barrel on Tuesday at midday, down sharply from USD110.30 at the London equities close on Friday. Gold stood at USD1,858.33 an ounce, down from USD1,906.75.

New York was pointed to a slightly lower open ahead of earnings reports from semiconductor maker Advanced Micro Devices, drugmaker Pfizer, and coffee-house chain Starbucks.

The Dow Jones Industrial Average was called down 0.2%, the S&P 500 down 0.1%, and the Nasdaq Composite down 0.3%, based on futures trading. The stock indices had closed up 0.3%, 0.6% and 1.6% respectively on Monday.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
12 Sep 2023 11:26

Hutchmed reports progress on two oncology fronts

(Sharecast News) - Hutchmed China reported significant strides in oncology research on Tuesday, completing patient enrollment for a bridging study of tazemetostat, and announcing pivotal results for the phase 3b clinical trial of savolitinib.

Read more
12 Sep 2023 10:26

IN BRIEF: Hutchmed China finalises patient enrolment for Tazemetostat

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Completes patient enrolment for bridging phase two study in China to evaluate the efficacy of cancer drug Tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma. Tazemetostat is approved by the US Food & Drug Administration for the treatment of advanced epithelioid sarcoma and R/R FL.

Read more
29 Aug 2023 13:38

Hutchmed tumour therapy candidate gets breakthrough designation

(Sharecast News) - Pharmaceuticals developer Hutchmed China announced on Tuesday that the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) has granted breakthrough therapy designation (BTD) to its investigational drug savolitinib.

Read more
29 Aug 2023 09:30

IN BRIEF: China grants Hutchmed's savolitinib breakthrough therapy tag

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Wins 'breakthrough therapy designation' in China for its gastric cancer treatment, savolitinib. The BTD is granted by the National Medical Products Administration. It is for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with mesenchymal epithelial transition factor amplification who have failed at least two lines of standard therapies. Hutchmed notes that MET-driven gastric cancer has a poor prognosis, and China grants a BTD to new drugs that treat life-threatening diseases for which there are no effective treatment options.

Read more
21 Aug 2023 08:46

Hutchmed China hails trial on sovleplenib meeting primary endpoint

(Alliance News) - Hutchmed (China) Ltd on Monday said a phase 3 trial evaluating the investigational use of sovleplenib met its primary endpoint.

Read more
21 Aug 2023 08:24

Hutchmed meets all endpoints in platelet disorder treatment trial

(Sharecast News) - Hutchmed China reported a breakthrough from its recent phase three trial in sovleplenib on Monday, reporting that it met its primary endpoint and all secondary endpoints for treating adult patients with primary immune thrombocytopenia - a platelet disorder - (ITP) in China.

Read more
31 Jul 2023 12:47

Hutchmed swings to profit after "sharpening goals and priorities"

(Alliance News) - Hutchmed (China) Ltd on Monday reported sharp first-half revenue growth, as a strategy change to boost its fortunes outside of China saw early fruit.

Read more
24 Jul 2023 15:46

UK earnings, trading statements calendar - next 7 days

Tuesday 25 July 
City of London Investment Group PLCTrading Statement
Compass Group PLCTrading Statement
Croda International PLCHalf Year Results
Games Workshop Group PLCFull Year Results
Greencore Group PLCTrading Statement
Hummingbird Resources PLCTrading Statement
MITIE Group PLCTrading Statement
Paragon Banking Group PLCTrading Statement
Reach PLCHalf Year Results
Smart Metering Systems PLCTrading Statement
Tristel PLCTrading Statement
Tyman PLCHalf Year Results
Unilever PLCHalf Year Results
Unite Group PLCHalf Year Results
Wednesday 26 July 
Aptitude Software Group PLCHalf Year Results
Breedon Group PLCHalf Year Results
Conduit Holdings LtdHalf Year Results
Ecora Resources PLCTrading Statement
Fresnillo PLCTrading Statement
FRP Advisory Group PLCFull Year Results
Gresham Technologies PLCHalf Year Results
Lloyds Banking Group PLCHalf Year Results
Marston's PLCTrading Statement
Nichols PLCHalf Year Results
Primary Health Properties PLCHalf Year Results
Rathbones Group PLCHalf Year Results
Revolution Bars Group PLCTrading Statement
Rio Tinto PLCHalf Year Results
Science Group PLCHalf Year Results
Van Elle Holdings PLCFull Year Results
Thursday 27 July 
Allianz Technology Trust PLCHalf Year Results
Antofagasta PLCHalf Year Results
Capital & Regional PLCHalf Year Results
Card Factory PLCTrading Statement
Checkit PLCTrading Statement
Drax Group PLCHalf Year Results
Deliveroo PLCHalf Year Results
Derwent London PLCHalf Year Results
Entain PLCHalf Year Results
Greencoat UK Wind PLCHalf Year Results
Global Connectivity PLCHalf Year Results
Hostelworld Group PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Lancashire Holdings LtdHalf Year Results
Mitchells & Butlers PLCTrading Statement
OSB Group PLCHalf Year Results
Persimmon PLCHalf Year Results
Petrofac LtdHalf Year Results
Redcentric PLCFull Year Results
S&U PLCTrading Statement
Savills PLCHalf Year Results
Secure Trust Bank PLCHalf Year Results
Spirax-Sarco Engineering PLCHalf Year Results
Videndum PLCHalf Year Results
Wheaton Precious Metals CorpHalf Year Results
Friday 28 July 
AIB Group PLCHalf Year Results
GCP Infrastructure Investments LtdTrading Statement
International Consolidated Airlines Group SAHalf Year Results
Intertek Group PLCHalf Year Results
Jardine Matheson Holdings LtdHalf Year Results
NatWest Group PLCHalf Year Results
PayPoint PLCFull Year Results
PayPoint PLCTrading Statement
Standard Chartered PLCHalf Year Results
YouGov PLCTrading Statement
Monday 31 July 
Hutchmed (China) LtdHalf Year Results
Pearson PLCHalf Year Results
Pod Point Group Holdings PLCHalf Year Results
Quartix Technologies PLCHalf Year Results
Spectris PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
20 Jul 2023 14:14

IN BRIEF: Hutchmed progresses fruquintinib designation and testing

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Granted breakthrough therapy designation, by the Center for Drug Evaluation of China's National Medical Products Administration, for oral inhibitor fruquintinib combined with PD-1 antibody sintilimab. BTD is for treatment of patients with previously treated advanced endometrial cancer.

Read more
10 Jul 2023 12:58

Hutchmed launches new phase one study in China

(Sharecast News) - Biopharmaceutical company Hutchmed China announced the launch of a phase one study in China for HMPL-415 on Monday - an investigational selective allosteric inhibitor that targeted Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2).

Read more
10 Jul 2023 08:53

IN BRIEF: Hutchmed starts study for tumour treatment in China

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases' treatment developer - Starts phase one study in China of its SHP2 inhibitor HMPL-415 for the treatment of advanced malignant solid tumours. First patient received their first dose on Thursday last week. Hutchmed expects up to 80 patients to take part in the study. SHP2 is a non-receptor protein tyrosine phosphatase which controls cell growth and cell migration.

Read more
16 Jun 2023 08:51

Hutchmed, Takeda Fresco-2 study published in The Lancet

(Alliance News) - Hutchmed (China) Ltd on Friday said phase three results for its Fresco-2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer, conducted alongside Takeda Pharmaceutical Co Ltd, were published in peer-reviewed journal, The Lancet.

Read more
16 Jun 2023 08:44

Hutchmed China's colorectal cancer study to be published

(Sharecast News) - Hutchmed China, alongside its partner Takeda, announced the publication of the phase three 'FRESCO-2' study results evaluating the use of fruquintinib in patients with previously-treated metastatic colorectal cancer (CRC) on Friday, in the Lancet medical journal.

Read more
15 Jun 2023 16:51

IN BRIEF: Hutchmed and Takeda get Europe marketing backing for drug

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases treatment developer - Says marketing authorisation application for fruquintinib, made alongside Tokyo-based Takeda Pharmaceutical Co Ltd, has been validated and caccepted by the European Medicines Agency. Fruquintinib is an inhibitor of vascular endothelial growth factor receptors used to treat cancers.

Read more
26 May 2023 13:13

US FDA gives priority to Hutchmed's colorectal cancer treatment

(Sharecast News) - Hutchmed China, in collaboration with Takeda, announced on Friday that the US Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) of fruquintinib.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.